InsuranceTom said:SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.
This is where I part company with the consensus forming above. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.
pat_auckland said:Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:
Weight: consistent downtrend, -1.9 lbs/week average
Fasting glucose (finger stick): stable at 84 mg/dL
Blood pressure (home): 119/74 average
Resting heart rate: 64 bpm (down from 80)
Waist circumference: down 14 inches total
The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.
PurityPaulOR said:The "earlier than weight loss explains" argument is weaker than this thread makes it sound.
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely! My cardiologist is thrilled.
If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
Did your prescriber agree with that reading, and if not what was their objection?
Dr.KarenChen said:Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely!
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 14 months of treatment.
The 5 criteria (and my journey):
- Waist circumference: 53" → 37" ✅ Resolved
- Triglycerides: 231 → 106 ✅ Resolved
- HDL: 37 → 53 ✅ Resolved
- Blood pressure: 141/97 → 119/73 ✅ Resolved
- Fasting glucose: 126 → 89 ✅ Resolved
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.